Micro-Tech Endoscopy Partners with Wision A.I. to Distribute its AI-assisted Polyp Detection Software in the U.S.

Announced at National Digestive Disease Week, Micro-Tech is the only GI endoscopy distributor of the EndoScreener colonoscopy technology in the U.S.

Micro-Tech Endoscopy USA, the U.S. subsidiary of the global medical device company Micro-Tech (Nanjing) Co. Ltd, which develops and supplies diagnostic and therapeutic devices in the gastroenterology space, has announced a business partnership with Wision A.I., a startup in the field of artificial intelligence-assisted diagnostics for optical medical imaging. Micro-Tech will be the U.S. GI endoscopy distributor of EndoScreener, an AI-assisted polyp detection software used during colonoscopy procedures.

Latest WebsiteHost.Review Insights: AiM Future Joins the Edge AI and Vision Alliance

“We believe that every patient deserves access to the best technology available in order to have the best chance for an optimal outcome—and our partnership with Wision does just that”

Wision A.I. gained FDA-clearance for EndoScreener in November 2021 following a U.S.-based clinical study¹ of 232 patients demonstrating that artificial intelligence-assisted colonoscopies with the Wision software resulted in fewer missed polyps. The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures.

“We believe that every patient deserves access to the best technology available in order to have the best chance for an optimal outcome—and our partnership with Wision does just that,” said Micro-Tech Endoscopy USA President Chris Li. “Together we are able to advance the early detection of more polyps and improve patient outcomes. More than 106,000 new cases of colon cancer are anticipated in 2022². This technology will ensure that more patients have early, accurate diagnosis so they have the best possible result. We see artificial intelligence playing a major role in increasing the detection of pre-cancerous polyps in the colon. This collaboration highlights Micro-Tech’s commitment to innovation that will serve patients and their health care providers.”

Browse The Complete News About WebsiteHost.Review : Cobalt Iron Earns Patent for Machine-Learning-Driven Authentication Control

In the U.S., colorectal cancer is the second most common cause of cancer deaths when numbers for men and women are combined³. EndoScreener software utilizes deep learning A.I. and Computer Aided Polyp Detection (CADe) systems to efficiently analyze and identify gland abnormalities in the lining of the colon, significantly improving the detection and precision capabilities of a standard colonoscopy.

“The CDC estimates that there should be roughly 11 to 13 million annual colonoscopies needed by 2024 to screen the eligible population⁴,” said Wision A.I. Co-Founder and Chief Executive Officer JingJia Liu. “Micro-Tech’s collaborative, patient-focused approach is the type of partner we need in order to improve patient outcomes at this scale. We believe that AI-assisted polyp detection in colonoscopy will greatly contribute to colorectal cancer screening and prevention—and Micro-Tech will help us get there.

Read More About WebsiteHost.Review News : Gradiant Acquires Synauta, Machine Learning Company, to Advance AI Technology in Water

[To share your insights with us, please write to admin@websitehost.review]